	US 12,371,699 B2
	Nucleic acids encoding CRISPR-associated proteins and uses thereof
Frédéric Chevessier-Tünnesen, Tübingen (DE); Marion Poenisch, Tübingen (DE); and Thomas Schlake, Tübingen (DE)
Assigned to CureVac SE, Tübingen (DE)
Filed by CureVac SE, Tübingen (DE)
Filed on Jul. 3, 2023, as Appl. No. 18/346,686.
Application 18/346,686 is a division of application No. 16/496,518, granted, now 11,739,335, previously published as PCT/EP2018/057552, filed on Mar. 23, 2018.
Claims priority of application No. PCT/EP2017/057110 (WO), filed on Mar. 24, 2017; and application No. PCT/EP2017/076775 (WO), filed on Oct. 19, 2017.
Prior Publication US 2023/0332163 A1, Oct. 19, 2023
Int. Cl. C12N 15/11 (2006.01); A61K 31/7088 (2006.01); A61K 48/00 (2006.01); C12N 9/22 (2006.01); C12N 15/113 (2010.01); C12N 15/67 (2006.01); C12N 15/62 (2006.01)

CPC C12N 15/67 (2013.01) [A61K 31/7088 (2013.01); A61K 48/0066 (2013.01); C12N 9/22 (2013.01); C12N 15/113 (2013.01); C12N 15/62 (2013.01); C12N 2310/20 (2017.05); C12N 2310/531 (2013.01)]

16 Claims

1. An artificial nucleic acid molecule comprising

a. at least one coding region encoding at least one CRISPR-associated protein, wherein the at least one coding region of said artificial nucleic acid molecule comprises or consists of a nucleic acid sequence at least 90% identical to the RNA sequence of SEQ ID NO: 14518, said sequence encoding a polypeptide that is at least 90% identical to SEQ ID NO: 1362;

b. at least one 5′ untranslated region (5′ UTR) element, which is heterologous relative to the at least one coding region; and

c. at least one 3′ untranslated region (3′ UTR) element, which is heterologous relative to the at least one coding region, wherein said artificial nucleic acid molecule is an RNA, which comprises a 5′ Cap and a Poly(A) sequence.